

Martin A Pule

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6390146/martin-a-pule-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

4,539
citations

19
h-index

49
g-index

49
ext. papers

5,469
ext. citations

8.7
avg, IF

4.61
L-index

#	Paper	IF	Citations
45	Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. <i>Scientific Reports</i> , 2021 , 11, 21902	4.9	1
44	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. <i>European Journal of Cancer</i> , 2021 ,	7.5	2
43	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. <i>Nature Medicine</i> , 2021 , 27, 1797-1805	50.5	18
42	Depletion of T cells Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. <i>Frontiers in Immunology</i> , 2021 , 12, 734246	8.4	2
41	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	17
40	Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. <i>Nature Cancer</i> , 2021 , 2, 629-642	15.4	10
39	Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. <i>Nature Communications</i> , 2021 , 12, 444	17.4	42
38	Chimeric antigen receptor T cells for gamma-delta T cell malignancies. <i>Leukemia</i> , 2021 ,	10.7	1
37	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3352-3363	2.2	5
36	A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats. <i>Scientific Reports</i> , 2020 , 10, 19168	4.9	1
35	Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	37
34	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. <i>Nature Medicine</i> , 2019 , 25, 1408-1414	50.5	211
33	Anti-CD1a CAR T cells to selectively target T-ALL. <i>Blood</i> , 2019 , 133, 2246-2247	2.2	7
32	Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans. <i>Blood</i> , 2019 , 134, 52-52	2.2	1
31	Imaging of X-Ray-Excited Emissions from Quantum Dots and Biological Tissue in Whole Mouse. <i>Scientific Reports</i> , 2019 , 9, 19223	4.9	6
30	An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. <i>Blood</i> , 2018 , 131, 746-758	2.2	90
29	Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2017 , 31, 1087-1095	10.7	47

28	Targeting the T cell receptor E-chain constant region for immunotherapy of T cell malignancies. <i>Nature Medicine</i> , 2017 , 23, 1416-1423	50.5	112
27	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. <i>PLoS ONE</i> , 2016 , 11, e0152196	3.7	36
26	Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. <i>Cytotherapy</i> , 2016 , 18, 1002-1011	4.8	114
25	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. <i>Cancer Research</i> , 2016 , 76, 2087-93	10.1	55
24	Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. <i>Blood</i> , 2014 , 124, 2514-22	2.2	41
23	A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. <i>Blood</i> , 2014 , 124, 1277-87	2.2	199
22	Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. <i>Human Gene Therapy Methods</i> , 2012 , 23, 376-86	4.9	82
21	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. <i>Blood</i> , 2011 , 118, 6050-6	2.2	813
20	Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. <i>Leukemia</i> , 2010 , 24, 1080-4	10.7	13
19	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. <i>Blood</i> , 2010 , 115, 925-35	2.2	610
18	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , 2008 , 14, 1264-70	50.5	919
17	Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. <i>Cytotherapy</i> , 2008 , 10, 526-39	4.8	10
16	Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. <i>Blood</i> , 2007 , 110, 2793-802	2.2	140
15	Transgenic Expression of IL15 Selectively Expands Antigen Specific Cytotoxic T Cells (CTLs) Enhancing Their Anti-Tumor Effect In Vivo.. <i>Blood</i> , 2006 , 108, 1721-1721	2.2	
14	Transgenic Expression of Inducible Caspase9 Suicide Gene for In Vivo Elimination of Antigen Specific Cytotoxic T Cells (CTLs) Engineered To Produce Cytokines.. <i>Blood</i> , 2006 , 108, 137-137	2.2	
13	An inducible caspase 9 safety switch for T-cell therapy. <i>Blood</i> , 2005 , 105, 4247-54	2.2	477
12	A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. <i>Molecular Therapy</i> , 2005 , 12, 933-41	11.7	365
11	T-Cells Redirected Against the kappa Light Chain of Human Immunoglobulins Target Mature B Cell Derived Malignancies In Vitro and In Vivo.. <i>Blood</i> , 2005 , 106, 612-612	2.2	1

10	Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells.. <i>Blood</i> , 2005 , 106, 5540-5540	2.2	
9	Three-Module Signaling Endo-Domain Artificial T-Cell Receptor Which Transmits CD28, OX40 and CD3- ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.. <i>Blood</i> , 2004 , 104, 1747-1747	2.2	2
8	Fas Down-Modulation in Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) Reduces Their Sensitivity to Fas/FasL-Induced Apoptosis.. <i>Blood</i> , 2004 , 104, 2647-2647	2.2	
7	Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.. <i>Blood</i> , 2004 , 104, 2112-2112	2.2	
6	Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.. <i>Blood</i> , 2004 , 104, 2102-2102	2.2	1
5	Epstein Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) Expressing an Anti-CD30 Chimeric T Cell Receptor (CTCR) for the Treatment of Hodgkin's Disease (HD).. <i>Blood</i> , 2004 , 104, 745-745	2.2	
4	Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.. <i>Blood</i> , 2004 , 104, 1743-1743		
3	Artificial T-cell receptors. <i>Cytotherapy</i> , 2003 , 5, 211-26	4.8	43
2	Genetically engineered T-cells for adoptive immunotherapy. <i>Current Opinion in Molecular Therapeutics</i> , 2002 , 4, 467-75		2
1	Gene transfer: methods and applications661-678		